Perrigo Says PSE Sales Up Again, Business From Leiner Helps Drive Growth
This article was originally published in The Tan Sheet
Sales of Perrigo's pseudoephedrine-containing OTC products increased in its latest quarter for the first time since nonprescription PSE drugs were placed behind the counter in October 2006, the private-labeler said Nov. 1
You may also be interested in...
With a major legal hurdle out of the way, Perrigo expects to launch its "largest opportunity" - the first store brand OTC proton pump inhibitor - by the end of March 2008, the firm said Nov. 1
An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders